Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Can Cancer Cells’ Drug Responses Be Predicted in Advance?

Can Cancer Cells’ Drug Responses Be Predicted in Advance?

Effective cancer treatment development depends on identifying individual genetic differences and designing appropriate drugs. Personalized treatment has gained importance, with research examining genetic differences in drug response. An important study appeared in November 2015 in Nature Biotechnology. A newly developed device can predict tumor-cell response before a drug is given to a patient.

In cancer research, genetic biomarkersare increasingly important. Genetic biomarkers are used to test targeted treatment efficacy, but most identified markers apply to few cancers and test reliability and precision remain problematic. Different strategies are therefore needed.

Inspired by antibiotic tests used for bacterial infections, researchers measured cancer-cell drug responses. Their device measures proliferation at very short intervals with high precision. The research used glioblastoma brain tumor cells and acute lymphocytic leukemia cells, exposing them to specific cancer-drug concentrations and measuring growth rates.

Cancer drug sensitivity testing is not new. Oncogram chemotherapy sensitivity tests have been tried for nearly 30 years, but long testing time and weak laboratory technique limited adoption. This technique using a “suspended microchannel resonator” offers innovations, especially small samples. Approximately 1000 cancer cells in 1 drop of blood may suffice. All analyses can finish in 1 day. Precision is 100 times greater than other methods, detecting even small proliferation changes.

According to the Research Results:

  • Known drug-sensitive cells slowed proliferation after treatment.
  • Resistant cells continued growing without a change in rate.

What Does This Study Mean Clinically?

  • Drugs can be tested on patient tumor samples with this device to select the most suitable treatment.
  • Analyses performed on tumor samples taken from the patient may identify the presence of treatment-resistant cells. This may allow a switch to other treatment strategies.

The research also guides investigation of resistance mechanisms. Genetic analysis of resistant cells detected by the device may identify resistance-causing genes.

Sources

Mark M Stevens,
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate,
Nature Biotechnology 34, 1161–1167 (2016)

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Can Cancer Cells’ Drug Responses Be Predicted in Advance?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy